(NYSE: EVMN) Evommune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Evommune's earnings in 2026 is -$94,668,000.On average, 14 Wall Street analysts forecast EVMN's earnings for 2026 to be -$121,193,882, with the lowest EVMN earnings forecast at -$131,950,864, and the highest EVMN earnings forecast at -$109,366,283. On average, 14 Wall Street analysts forecast EVMN's earnings for 2027 to be -$132,154,100, with the lowest EVMN earnings forecast at -$155,424,603, and the highest EVMN earnings forecast at -$84,596,915.
In 2028, EVMN is forecast to generate -$132,999,707 in earnings, with the lowest earnings forecast at -$156,491,591 and the highest earnings forecast at -$103,650,275.